<html><head><link rel="stylesheet" type="text/css" href="css/style.css"></head><body><div id="main"><h1>Scignal</h1></div> <div class="container"><div class="row"><div class="search"><h2>All Results for : "Checkpoint inhibitor" and "resistance"</a></h2></div><table><tr><td class="head"><h3>BioRxiv</h3></td><td class="head"><h3>PubMed</h3></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Combining radiomics and mathematical modeling to elucidate mechanisms of resistance to immune checkpoint blockade in non-small cell lung cancer</h4><p><a href="https://www.biorxiv.org/content/10.1101/190561v1">Link</a></p><p><b>Date:</b> 2017-09-22</p><p><b>Authors:</b> Daryoush Saeed-Vafa ... Jill A. Gallaher</p><p><b>Downloads:</b> 785</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Immune therapies have shown promise in a number of cancers, and clinical trials using the anti-PD-L1/PD-1 checkpoint inhibitor in lung cancer have been successful for a number of patients.  However, some patients either do not respond to the treatment or have cancer recurrence after an initial response.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Combining microenvironment normalization strategies to improve cancer immunotherapy.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32015113">Link</a></p><p><b>Date:</b> 2020-02-05</p><p><b>Authors:</b> Fotios Mpekris ...  Rakesh K Jain</p><p><b>Journal:</b> Proc. Natl. Acad. Sci. U.S.A.</p><p><b>IF (7 or above):</b> 9.35</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Advances in immunotherapy have revolutionized the treatment of multiple cancers.  Unfortunately, tumors usually have impaired blood perfusion, which limits the delivery of therapeutics and cytotoxic immune cells to tumors and also results in hypoxia-a hallmark of the abnormal tumor microenvironment  ....</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor resistant HER2-positive breast cancer</h4><p><a href="https://www.biorxiv.org/content/10.1101/671198v2">Link</a></p><p><b>Date:</b> 2019-06-14</p><p><b>Authors:</b> Qingfei Wang ... Siyuan Zhang</p><p><b>Downloads:</b> 611</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Development of acquired resistance to targeted cancer therapy is one of the most significant clinical challenges.  Acquiring resistance under drug selection pressure is a result of evolutionary adaptation to a complex and dynamic tumor microenvironment (TME).</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Treating non-responders: pitfalls and implications for cancer immunotherapy trial design.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32171307">Link</a></p><p><b>Date:</b> 2020-03-16</p><p><b>Authors:</b> Zhenzhen Xu ...  Bin Zhu</p><p><b>Journal:</b> J Hematol Oncol</p><p><b>IF (7 or above):</b> 8.71</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> BACKGROUND: Conventional trial design and analysis strategies fail to address the typical challenge of immune-oncology (IO) studies: only a limited percentage of treated patients respond to the experimental treatment.  Treating non-responders, we hypothesize, would in part drive non-proportional haz ....</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Tankyrase inhibition sensitizes melanoma to PD-1 immune checkpoint blockade in syngeneic mouse models</h4><p><a href="https://www.biorxiv.org/content/10.1101/526343v1">Link</a></p><p><b>Date:</b> 2019-01-22</p><p><b>Authors:</b> Jo Waaler ... Stefan Krauss</p><p><b>Downloads:</b> 592</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> The development of immune checkpoint inhibitors represents a major breakthrough in cancer therapy.  Nevertheless, a substantial number of patients fail to respond to checkpoint pathway blockade.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: T lymphocyte-targeted immune checkpoint modulation in glioma.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32051289">Link</a></p><p><b>Date:</b> 2020-02-13</p><p><b>Authors:</b> William James Kelly ...  Mark Gilbert</p><p><b>Journal:</b> J Immunother Cancer</p><p><b>IF (7 or above):</b> 8.66</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Immunomodulatory therapies targeting inhibitory checkpoint molecules have revolutionized the treatment of solid tumor malignancies.  Concerns about whether systemic administration of an immune checkpoint inhibitor could impact primary brain tumors were answered with the observation of definitive res ....</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Understanding inhibitor resistance in Mps1 kinase through novel biophysical assays and structures</h4><p><a href="https://www.biorxiv.org/content/10.1101/112086v2">Link</a></p><p><b>Date:</b> 2017-02-27</p><p><b>Authors:</b> Yoshitaka Hiruma ... Anastassis Perrakis</p><p><b>Downloads:</b> 453</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Monopolar spindle 1 (Mps1/TTK) is a protein kinase essential in mitotic checkpoint signalling, preventing anaphase until all chromosomes are properly attached to spindle microtubules.  Mps1 has emerged as a potential target for cancer therapy, and a variety of compounds have been developed to inhibit its kinase activity.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: On the mechanism of anti-CD39 immune checkpoint therapy.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32098829">Link</a></p><p><b>Date:</b> 2020-02-26</p><p><b>Authors:</b> David Allard ...  John Stagg</p><p><b>Journal:</b> J Immunother Cancer</p><p><b>IF (7 or above):</b> 8.66</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> With the coming of age of cancer immunotherapy, the search for new therapeutic targets has led to the identification of immunosuppressive adenosine as an important regulator of antitumor immunity.  This resulted in the development of selective inhibitors targeting various components of the adenosine ....</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: A novel role for the HLH protein Inhibitor of Differentiation 4 (ID4) in the DNA damage response in basal-like breast cancer.</h4><p><a href="https://www.biorxiv.org/content/10.1101/281196v1">Link</a></p><p><b>Date:</b> 2018-03-14</p><p><b>Authors:</b> Laura A Baker ... Alexander Swarbrick</p><p><b>Downloads:</b> 351</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Basal-like breast cancer (BLBC) is a poorly characterised, heterogeneous disease.  Patients are diagnosed with aggressive, high-grade tumours and often relapse with chemotherapy resistance.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Identification of tumor immune infiltration-associated lncRNAs for improving prognosis and immunotherapy response of patients with non-small cell lung cancer.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32041817">Link</a></p><p><b>Date:</b> 2020-02-11</p><p><b>Authors:</b> Jie Sun ...  Meng Zhou</p><p><b>Journal:</b> J Immunother Cancer</p><p><b>IF (7 or above):</b> 8.66</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> BACKGROUND: Increasing evidence has demonstrated the functional relevance of long non-coding RNAs (lncRNAs) to immunity regulation and the tumor microenvironment in non-small cell lung cancer (NSCLC).  However, tumor immune infiltration-associated lncRNAs and their value in improving clinical outcom ....</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer</h4><p><a href="https://www.biorxiv.org/content/10.1101/2020.01.10.902528v2">Link</a></p><p><b>Date:</b> 2020-01-11</p><p><b>Authors:</b> Raffaella Soldi ... Sunil Sharma</p><p><b>Downloads:</b> 347</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Chromatin remodeling SWItch/Sucrose-NonFermentable (SWI/SNF) complexes, initially identified in yeast 20 years ago, are evolutionarily conserved multi-subunit protein complexes that use the energy from hydrolysis of adenosine triphosphate (ATP) to remodel nucleosome structure and modulate transcription.  Mutations in proteins of SWI/SNF complexes occur in 20% of human cancers including ovarian cancer (OC).</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Sixth Immunotherapy of Cancer conference (ITOC): advances and perspectives-a meeting report.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32114499">Link</a></p><p><b>Date:</b> 2020-03-02</p><p><b>Authors:</b> Catarina Pinto ...  Sebastian Kobold</p><p><b>Journal:</b> J Immunother Cancer</p><p><b>IF (7 or above):</b> 8.66</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Immunotherapy has moved to the forefront of cancer treatment, illustrated by the accelerating pace of novel therapy approvals.  In this complex environment, scientists rely on cutting edge conferences to stay informed.</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Inhibitor of the spindle assembly checkpoint surpasses apoptosis sensitizer in synergy with taxanes</h4><p><a href="https://www.biorxiv.org/content/10.1101/414359v1">Link</a></p><p><b>Date:</b> 2018-09-11</p><p><b>Authors:</b> Teng-Long Han ... Hang Sha</p><p><b>Downloads:</b> 274</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> The antitumor effect of taxanes have been attributed to their ability to induce mitotic arrest through activation of the spindle assembly checkpoint.  Cell death following prolonged mitotic arrest is mediated by the intrinsic apoptosis pathway.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32079617">Link</a></p><p><b>Date:</b> 2020-02-22</p><p><b>Authors:</b> Hanne Lind ...  Jeffrey Schlom</p><p><b>Journal:</b> J Immunother Cancer</p><p><b>IF (7 or above):</b> 8.66</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Immunosuppressive entities in the tumor microenvironment (TME) remain a major impediment to immunotherapeutic approaches for a majority of patients with cancer.  While the immunosuppressive role of transforming growth factor-β (TGF-β) in the TME is well known, clinical studies to date with anti-TGF- ....</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Therapeutically actionable PAK4 is amplified, overexpressed and involved in bladder cancer progression</h4><p><a href="https://www.biorxiv.org/content/10.1101/740316v1">Link</a></p><p><b>Date:</b> 2019-08-20</p><p><b>Authors:</b> Darshan S Chandrashekar ... Guru Sonpavde</p><p><b>Downloads:</b> 182</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Muscle-invasive bladder carcinomas (MIBCs) are aggressive genitourinary malignancies.  Disease incidence and survival rates vary based on aggressiveness and treatment options.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Dual pH-sensitive nanodrug blocks PD-1 immune checkpoint and uses T cells to deliver NF-κB inhibitor for antitumor immunotherapy.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32076650">Link</a></p><p><b>Date:</b> 2020-02-22</p><p><b>Authors:</b> Zecong Xiao ...  Xintao Shuai</p><p><b>Journal:</b> Sci Adv</p><p><b>IF (7 or above):</b> 12.53</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> The response to programmed cell death protein-1 (PD-1)/programmed death ligand-1 (PD-L1) blockade in cancer immunotherapy is limited because of multiple immune evasion mechanisms.  Here, a previously unknown strategy is proposed to synergize the nuclear factor κB (NF-κB) inhibition and PD-1 blockade ....</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: CAR T cells for solid tumors: genome-wide dysfunction signature confirms value of c-Jun overexpression, but signals heterogeneity</h4><p><a href="https://www.biorxiv.org/content/10.1101/2020.02.07.939033v1">Link</a></p><p><b>Date:</b> 2020-02-11</p><p><b>Authors:</b> Mostapha Benhenda</p><p><b>Downloads:</b> 134</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Chimeric antigen receptor (CAR) T cells still have limited effects in cancer, and especially in solid tumors, due to T cell dysfunction and exhaustion.  CAR T cells overexpressing c-Jun (JUN CAR T cells) have been introduced to solve this problem.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Annexin A5 as an immune checkpoint inhibitor and tumor-homing molecule for cancer treatment.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32111835">Link</a></p><p><b>Date:</b> 2020-02-29</p><p><b>Authors:</b> Tae Heung Kang ...  Chien-Fu Hung</p><p><b>Journal:</b> Nat Commun</p><p><b>IF (7 or above):</b> 11.8</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> The interaction between immune cells and phosphatidylserine (PS) molecules exposed on the surface of apoptotic-tumor bodies, such as those induced by chemotherapies, contributes to the formation of an immunosuppressive tumor microenvironment (TME).  Annexin A5 (AnxA5) binds with high affinity to PS  ....</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: RIPK3 inhibition prevents KRAS mutant p53 deficient lung tumor progression by impeding MDSCs</h4><p><a href="https://www.biorxiv.org/content/10.1101/853978v1">Link</a></p><p><b>Date:</b> 2019-11-25</p><p><b>Authors:</b> Asha Jayakumar</p><p><b>Downloads:</b> 96</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> KRAS mutant p53 deficient (KP) non-small cell lung carcinoma (NSCLC) lacks targeted therapies.  Existing treatments for lung cancer cause resistance and result in toxicities requiring novel effective therapies.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32051401">Link</a></p><p><b>Date:</b> 2020-02-13</p><p><b>Authors:</b> Elena Galvani ...  Richard Marais</p><p><b>Journal:</b> Nat Commun</p><p><b>IF (7 or above):</b> 11.8</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Although immune checkpoint inhibitors (ICIs) have achieved unprecedented results in melanoma, the biological features of the durable responses initiated by these drugs remain unknown.  Here we show the genetic and phenotypic changes induced by treatment with programmed cell death-1 (PD-1) blockade i ....</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Suppression of Docetaxel induced apoptosis in Survivin-depleted cells due to failure of sustained mitotic block</h4><p><a href="https://www.biorxiv.org/content/10.1101/834259v1">Link</a></p><p><b>Date:</b> 2019-11-07</p><p><b>Authors:</b> Teng-Long Han ... Zhi-Xin Jiang</p><p><b>Downloads:</b> 73</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> The antitumor effect of taxanes have been attributed to their ability to induce mitotic arrest through activation of the spindle assembly checkpoint.  Cell death following prolonged mitotic arrest is mediated by the intrinsic apoptosis pathway.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32034147">Link</a></p><p><b>Date:</b> 2020-02-08</p><p><b>Authors:</b> Christopher B Driscoll ...  Richard G Vile</p><p><b>Journal:</b> Nat Commun</p><p><b>IF (7 or above):</b> 11.8</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> APOBEC3B, an anti-viral cytidine deaminase which induces DNA mutations, has been implicated as a mediator of cancer evolution and therapeutic resistance.  Mutational plasticity also drives generation of neoepitopes, which prime anti-tumor T cells.</p></div></td></div></tr><tr><div class="row"><td></td><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32165639">Link</a></p><p><b>Date:</b> 2020-03-13</p><p><b>Authors:</b> Ellen Brenner ...  Martin Röcken</p><p><b>Journal:</b> Nat Commun</p><p><b>IF (7 or above):</b> 11.8</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Immune checkpoint blockade (ICB)-based or natural cancer immune responses largely eliminate tumours.  Yet, they require additional mechanisms to arrest those cancer cells that are not rejected.</p></div></td></div></tr><tr><div class="row"><td></td><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32075964">Link</a></p><p><b>Date:</b> 2020-02-22</p><p><b>Authors:</b> Kwoneel Kim ...  Jung Kyoon Choi</p><p><b>Journal:</b> Nat Commun</p><p><b>IF (7 or above):</b> 11.8</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Neoantigen burden is regarded as a fundamental determinant of response to immunotherapy.  However, its predictive value remains in question because some tumours with high neoantigen load show resistance.</p></div></td></div></tr><tr><div class="row"><td></td><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32061257">Link</a></p><p><b>Date:</b> 2020-02-17</p><p><b>Authors:</b> Jia-Qiao Fan ...  Jianxun Song</p><p><b>Journal:</b> Mol. Cancer</p><p><b>IF (7 or above):</b> 11.35</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Pancreatic ductal adenocarcinoma (PDAC) is an incurable cancer resistant to traditional treatments, although a limited number of early-stage patients can undergo radical resection.  Immunotherapies for the treatment of haematological malignancies as well as solid tumours have been substantially impr ....</p></div></td></div></tr><tr><div class="row"><td></td><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Predictable modulation of cancer treatment outcomes by the gut microbiota.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32138779">Link</a></p><p><b>Date:</b> 2020-03-06</p><p><b>Authors:</b> Yoshitaro Heshiki ...  Gianni Panagiotou</p><p><b>Journal:</b> Microbiome</p><p><b>IF (7 or above):</b> 10.35</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> The gut microbiota has the potential to influence the efficacy of cancer therapy.  Here, we investigated the contribution of the intestinal microbiome on treatment outcomes in a heterogeneous cohort that included multiple cancer types to identify microbes with a global impact on immune response.</p></div></td></div></tr></table></div><hr></div></body></html>